Does the U.S. biotech industry deserve a bailout?

The global economic downturn has created a world of extraordinary government intervention in markets and industry. But what industries and/or companies deserve to be saved, and which should be allowed to fend for themselves? U.S. biotech (and small pharmaceutical companies) have been hit particularly hard by the ongoing crisis, but have so far been denied access to the government's umbrella. In this Industry Voices column, contributor Daniel  Nevrivy, Ph.D., argues that, unlike automakers, government support of the U.S. biotech industry is well worth the investment. Article